{"id":"NCT00950352","sponsor":"Perry Renshaw","briefTitle":"Citicoline Treatment of Methamphetamine Dependence","officialTitle":"Citicoline Treatment of Methamphetamine Dependence","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-01","primaryCompletion":"2012-12","completion":"2012-12","firstPosted":"2009-07-31","resultsPosted":"2015-02-11","lastUpdate":"2015-02-11"},"enrollment":104,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Methamphetamine Dependence"],"interventions":[{"type":"DRUG","name":"Citicoline","otherNames":["CDP-Choline"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Citicoline","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the study is to determine if citicoline (a nutritional supplement) is effective in helping people reduce their dependence on methamphetamine. The investigators will use neuroimaging to look at the structure and chemical make up of the brain at the start of the study and after 8-9 weeks of treatment of citicoline or placebo.","primaryOutcome":{"measure":"Methamphetamine Dependent Subjects Treated With Citicoline vs Placebo","timeFrame":"8 weeks, assessed twice weekly starting week1","effectByArm":[{"arm":"Citicoline","deltaMin":0.3025,"sd":0.16498},{"arm":"Placebo","deltaMin":0.385,"sd":0.34547}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":13},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["http://brain.utah.edu/","http://www.nida.nih.gov/"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":72},"commonTop":["General (Weight loss, Headache, Cold/flu-lie symptoms, fatigue, pulmonary)","Gatsrointestinal symptoms","Psychiatric"]}}